维拉多细胞血症:最佳管理障碍和策略
Andrea Duminuco1,2, Patrick Harrington1, Claire Harrison1
1Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
多细胞血病 (PV) 管理需要全面的方法来改善生活质量和预防并发症. 最近的进展包括新疗法,以及传统的治疗方法,如静脉切除和氧化碳胺.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 内部医学 内部医学
背景情况:
- 多细胞血症真 (PV) 是一种骨髓增殖性瘤,影响生活质量,并导致严重的并发症.
- 尽管知识不断增长,但PV需要多方面的管理策略来控制症状并减少血栓/出血风险.
研究的目的:
- 审查当前和不断变化的治疗场景对于真菌多细胞瘤.
- 突出综合管理对缓解症状和延长生存时间的重要性.
主要方法:
- 关于多细胞血症管理的当前文献的综述.
- 分析既有和新兴的治疗选择.
- 讨论静脉切割,氧化碳胺,抗血小板治疗,干扰素和JAK抑制剂的作用.
主要成果:
- 静脉切割和氧化碳胺仍然是核心,通常是用抗血小板治疗.
- 干扰素和亚努斯激酶 (JAK) 抑制剂代表了治疗武器库的新增.
- 针对性治疗的研究正在扩大治疗选择.
结论:
- 多细胞血症的管理已经显著发展,为患者提供了更好的治疗结果.
- 传统和新型疗法的结合对于有效的光伏治疗至关重要.
- 目前正在进行的研究有望在个性化多细胞瘤治疗方面取得进一步的进展.
更多相关视频
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
12:04Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
相关概念视频
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
